Emily M. Leproust Sells 1,654 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,654 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $44.90, for a total transaction of $74,264.60. Following the transaction, the chief executive officer now owns 673,064 shares in the company, valued at approximately $30,220,573.60. The trade was a 0.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Twist Bioscience Stock Performance

Shares of TWST traded up $0.33 during trading hours on Thursday, reaching $49.23. The stock had a trading volume of 486,846 shares, compared to its average volume of 939,671. The stock has a market capitalization of $2.92 billion, a PE ratio of -13.68 and a beta of 1.82. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company’s 50-day moving average is $45.51 and its two-hundred day moving average is $46.72.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TWST shares. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Robert W. Baird boosted their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $51.90.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Principal Financial Group Inc. raised its holdings in Twist Bioscience by 210.2% in the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after buying an additional 83,287 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after acquiring an additional 20,035 shares during the last quarter. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares during the period. FMR LLC grew its stake in shares of Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after purchasing an additional 12,327 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after purchasing an additional 21,357 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.